Bevacizumab treatment in multifocal lymphangioendotheliomatosis with thrombocytopenia.
Multifocal lymphangioendotheliomatosis with thrombocytopenia (MLT) is a rare disorder characterized by a proliferation of cutaneous and gastrointestinal (GI) lesions that have characteristics of both lymphatic and vascular lesions. Thrombocytopenia is associated with this syndrome and is thought to represent platelet destruction within the lesions. The natural history is one of multiple, life-threatening episodes of GI bleeding. We report the successful use of bevacizumab in this disease, an antibody to the vascular endothelial growth factor.
Kline
Ronald M
RM
Pediatric Division, Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada 89109, USA. ronald.kline@usoncology.com
Buck
Laura Marcu
LM
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000068258:Bevacizumab; D002675:Child, Preschool; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D011241:Prednisone / Q000008:administration & dosage; D011899:Ranitidine / Q000008:administration & dosage; D013392:Sucralfate / Q000008:administration & dosage; D013683:Telangiectasia, Hereditary Hemorrhagic / Q000150:complications / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000188:drug therapy* / Q000209:etiology; D014750:Vincristine / Q000008:administration & dosage
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab; D013392:Sucralfate; D014750:Vincristine; D011899:Ranitidine; D011241:Prednisone